Acquisition Background InferMed was acquired by Elsevier in 2015, signaling a potential shift in product strategy, integration with a broader medical information ecosystem, and opportunities to align CDS technologies with Elsevier’s data assets and customers.

Clinical Decision Support Strength With Arezzo and MACRO EDC, the company specializes in clinical decision support and evidence-based care at the point of care, presenting a strong selling point to healthcare providers and research institutions seeking digital tools to standardize practice and improve outcomes.

Global Reach Solutions are accessed over a million times per month across Europe, North America, and Australasia, indicating demand in multiple regions and potential for upsell through regionalized features, support, or expansion of deployment for multinational health systems.

Small to Mid-Sized Focus With 11-50 employees and <$1M revenue, InferMed operates as a lean, innovative player, suggesting opportunities to partner with larger tech or life sciences firms for scale, while offering tailored, high-value CDS deployments for mid-tier hospitals and research centers.

Product and Innovation Recognition Queen’s Award for Enterprise in Innovation in 2012 highlights credibility in healthcare decision-support technology, which can be leveraged in sales pitches when approaching public sector clients or institutions seeking proven innovation credentials.